Industrial Production of Therapeutic Proteins: Cell Lines, Cell Culture, and Purification

Chapter

Abstract

The biotechnology and pharmaceutical industries have seen a recent surge in the development of biological drug products manufactured from engineered mammalian cell lines. Since the hugely successful launch of human tissue plasminogen activator in 1987 and erythropoietin in 1988, the biopharmaceutical market has grown immensely. Global sales in 2003 exceeded US $30 billion [1]. Currently, a total of 108 biotherapeutics are approved and available to patients (Table 32.1). In addition, 324 medically related, biotechnology-derived medicines for nearly 150 diseases are in clinical trials or under review by the US Food and Drug Administration [2]. These biopharmaceutical candidates promise to bring more and better treatments to patients. Compared to small molecule drugs, biotherapeutics show exquisite specificity with fewer off-target interactions and improved safety profiles. Protein engineering technologies have advanced to create protein drugs with improved efficacy, specificity, stability, pharmacokinetics, and solubility. Strategies that have been employed to implement these changes include mutagenesis, recombination, and other directed evolution methods, as well as rational design and structure-based computational approaches [3–7]. These advanced protein engineering technologies are creating novel drug designs and clever treatment strategies that are fuelling the biopharmaceutical market growth.

Keywords

Vortex Surfactant Fermentation Torque Lactate 

Notes

Acknowledgements

The authors would like thank all the colleagues who helped in many invaluable ways in the production of this chapter, in particular, Marie Ary, Kenton Abel, Bassil Dahiyat, Joyce Morrison, and Christopher O’Brien.

References

  1. 1.
    Walsh G (2003) Biopharmaceutical benchmarks—2003. Nat Biotechnol 21:865–870CrossRefGoogle Scholar
  2. 2.
    PhRMA (2004) 324 biotechnology medicines in testing promise to bolster the arsenal against disease. New medicines in development. Accessed Oct 25, 2004. http://www.phrma.org/newmedicines/biotech/
  3. 3.
    Graddis TJ, Remmele RL Jr, McGrew JT (2002) Designing proteins that work using recombinant technologies. Curr Pharm Biotechnol 3:285–297CrossRefGoogle Scholar
  4. 4.
    Brekke OH, Loset GA (2003) New technologies in therapeutic antibody development. Curr Opin Pharmacol 3:544–550CrossRefGoogle Scholar
  5. 5.
    Lazar GA, Marshall SA, Plecs JJ, Mayo SL, Desjarlais JR (2003) Designing proteins for therapeutic applications. Curr Opin Struct Biol 13:513–518CrossRefGoogle Scholar
  6. 6.
    Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR (2003) Rational design and engineering of therapeutic proteins. Drug Discov Today 8:212–221CrossRefGoogle Scholar
  7. 7.
    Vasserot AP, Dickinson CD, Tang Y, Huse WD, Manchester KS, Watkins JD (2003) Optimization of protein therapeutics by directed evolution. Drug Discov Today 8:118–126CrossRefGoogle Scholar
  8. 8.
    Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22:1393–1398CrossRefGoogle Scholar
  9. 9.
    Arden N, Nivtchanyong T, Betenbaugh MJ (2004) Cell engineering blocks stress and improves biotherapeutic production. Bioprocessing 3:23–28Google Scholar
  10. 10.
    Running Deer J, Allison DS (2004) High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1alpha gene. Biotechnol Prog 20:880–889CrossRefGoogle Scholar
  11. 11.
    Brinster RL, Allen JM, Behringer RR, Gelinas RE, Palmiter RD (1988) Introns increase transcriptional efficiency in transgenic mice. Proc Natl Acad Sci U S A 85:836–840CrossRefGoogle Scholar
  12. 12.
    Palmiter RD, Sandgren EP, Avarbock MR, Allen DD, Brinster RL (1991) Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci U S A 88:478–482CrossRefGoogle Scholar
  13. 13.
    Pestova TV, Lomakin IB, Hellen CU (2004) Position of the CrPV IRES on the 40S subunit and factor dependence of IRES/80S ribosome assembly. EMBO Rep 5:906–913CrossRefGoogle Scholar
  14. 14.
    Zahn-Zabal M, Kobr M, Girod PA, Imhof M, Chatellard P, de Jesus M, Wurm F, Mermod N (2001) Development of stable cell lines for production or regulated expression using matrix attachment regions. J Biotechnol 87:29–42CrossRefGoogle Scholar
  15. 15.
    Kim JM, Kim JS, Park DH, Kang HS, Yoon J, Baek K, Yoon Y (2004) Improved recombinant gene expression in CHO cells using matrix attachment regions. J Biotechnol 107:95–105CrossRefGoogle Scholar
  16. 16.
    Harland L, Crombie R, Anson S, deBoer J, Ioannou PA, Antoniou M (2002) Transcriptional regulation of the human TATA binding protein gene. Genomics 79:479–482CrossRefGoogle Scholar
  17. 17.
    Wong TK, Newmann E (1982) Electric-field mediated gene-transfer. Biochem Biophys Res Commun 107:584–587CrossRefGoogle Scholar
  18. 18.
    Kichler A (2004) Gene transfer with modified polyethylenimines. J Gene Med 6(Suppl 1):S3–10CrossRefGoogle Scholar
  19. 19.
    Cockett MI, Bebbington CR, Yarranton GT (1990) High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification. Biotechnol (N Y) 8:662–667CrossRefGoogle Scholar
  20. 20.
    Lucas BK, Giere LM, DeMarco RA, Shen A, Chisholm V, Crowley CW (1996) High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector. Nucleic Acids Res 24:1774–1779CrossRefGoogle Scholar
  21. 21.
    Kim SJ, Lee GM (1999) Cytogenetic analysis of chimeric antibody-producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their5t stability in the absence of selective pressure. Biotechnol Bioeng 64:741–749CrossRefGoogle Scholar
  22. 22.
    Fann CH, Guirgis F, Chen G, Lao MS, Piret JM (2000) Limitations to the amplification and stability of human tissue-type plasminogen activator expression by Chinese hamster ovary cells. Biotechnol Bioeng 69:204–212CrossRefGoogle Scholar
  23. 23.
    Yoshikawa T, Nakanishi F, Ogura Y, Oi D, Omasa T, Katakura Y, Kishimoto M, Suga K (2000) Amplified gene location in chromosomal DNA affected recombinant protein production and stability of amplified genes. Biotechnol Prog 16:710–715CrossRefGoogle Scholar
  24. 24.
    Brezinsky SC, Chiang GG, Szilvasi A, Mohan S, Shapiro RI, MacLean A, Sisk W, Thill G (2003) A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity. J Immunol Methods 277:141–155CrossRefGoogle Scholar
  25. 25.
    Ham RG (1981) Tissue growth factors. In: Baserga R (ed) Handbook of experimental pharmacology. Springer, New York, p 13Google Scholar
  26. 26.
    Sato GH, Pardee A, Sirbasku DA (eds) (1982) Growth of cells in hormonally defined media, cold spring harbor conference on cell proliferation, vol 9. Cold Spring Harbor Press, Cold Spring Harbor, NYGoogle Scholar
  27. 27.
    Fletcher T (2005) Designing culture media for recombinant protein production: A rational approach. BioProcess Int 3:30–36Google Scholar
  28. 28.
    Lee GM, Kim EJ, Kim NS, Yoon SK, Ahn YH, Song JY (1999) Development of a serum-free medium for the production of erythropoietin by suspension culture of recombinant Chinese hamster ovary cells using a statistical design. J Biotechnol 69:85–93CrossRefGoogle Scholar
  29. 29.
    Liu C, Chu I, Hwang S (2001) Factorial designs combined with the steepest ascent method to optimize serum-free media for CHO cells. Enzyme Microb Technol 28:314–321CrossRefGoogle Scholar
  30. 30.
    Chun C, Heineken K, Szeto D, Ryll T, Chamow S, Chung JD (2003) Application of factorial design to accelerate identification of CHO growth factor requirements. Biotechnol Prog 19:52–57CrossRefGoogle Scholar
  31. 31.
    Allison DW, Aboytes KA, Fong DK, Leugers SL, Johnson TK, Loke HN, Donahue LM (2005) Development and optimization of cell culture media: Genomic and proteomic approaches. BioProcess Int 31:38–45Google Scholar
  32. 32.
    Zhu MM, Lee ES, Hermans WR, Wasilko DJ (2001) Overview and serum-free medium development for mammalian cell culture. Fourth Conference on recent advances in fermentation technology (RAFTIV), Nov 11–13, Long Beach, CAGoogle Scholar
  33. 33.
    Varley J, Birch J (1999) Reactor design for large scale suspension animal cell culture. Cytotechnol 29:177–205CrossRefGoogle Scholar
  34. 34.
    Ozturk SS (1996) Engineering challenges in high density cell culture systems. Cytotechnol 22:3–16CrossRefGoogle Scholar
  35. 35.
    Myers KJ, Reeder MF, Fasano JB (2002) Optimize mixing by using the proper baffles. Chem Eng Progress 98:42–47Google Scholar
  36. 36.
    Chisti Y (1993) Animal cell culture in stirred bioreactors: Observations on scale-up. Bioprocess Eng 9:191–196CrossRefGoogle Scholar
  37. 37.
    Pattison RN, Swamy J, Mendenhall B, Hwang C, Frohlich BT (2000) Measurement and control of dissolved carbon dioxide in mammalian cell culture processes using an in situ fiber optic chemical sensor. Biotechnol Prog 16:769–774CrossRefGoogle Scholar
  38. 38.
    Dowd JE, Jubb A, Kwok KE, Piret JM (2003) Optimization and control of perfusion cultures using a viable cell probe and cell specific perfusion rates. Cytotechnol 42:35–45CrossRefGoogle Scholar
  39. 39.
    Noll T, Biselli M (1998) Dielectric spectroscopy in the cultivation of suspended and immobilized hybridoma cells. J Biotechnol 63:187–198CrossRefGoogle Scholar
  40. 40.
    Gupta A, Rao G (2003) A study of oxygen transfer in shake flasks using a non-invasive oxygen sensor. Biotechnol Bioeng 84:351–358CrossRefGoogle Scholar
  41. 41.
    Ge X, Kostov Y, Rao G (2005) Low-cost noninvasive optical CO2 sensing system for fermentation and cell culture. Biotechnol Bioeng 89:329–334CrossRefGoogle Scholar
  42. 42.
    Singh V (1999) Disposable bioreactor for cell culture using wave-induced agitation. Cytotechnol 30:149–158CrossRefGoogle Scholar
  43. 43.
    Ozturk SS (2005) Batch versus perfusion: a real case comparison of highly developed cell culture processes for the production of monoclonal antibodies. 229th National Meeting American Chemical Society, Mar 13–17, San Diego, CAGoogle Scholar
  44. 44.
    Voisard D, Meuwly F, Ruffieux PA, Baer G, Kadouri A (2003) Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells. Biotechnol Bioeng 82:751–765CrossRefGoogle Scholar
  45. 45.
    Alrubeai M, Singh RP, Emery AN, Zhang Z (1995) Cell cycle and cell size dependence of susceptibility to hydrodynamic forces. Biotechnol Bioeng 46:88–92CrossRefGoogle Scholar
  46. 46.
    Alrubeai M, Singh RP, Goldman MH, Emery AN (1995) Death mechanisms of animal cells in conditions of intensive agitation. Biotechnol Bioeng 45:463–472CrossRefGoogle Scholar
  47. 47.
    Gregoriades N, Clay J, Ma N, Koelling K, Chalmers JJ (2000) Cell damage of microcarrier cultures as a function of local energy dissipation created by a rapid extensional flow. Biotechnol Bioeng 69:171–182CrossRefGoogle Scholar
  48. 48.
    Ma N, Koelling KW, Chalmers JJ (2002) Fabrication and use of a transient contractional flow device to quantify the sensitivity of mammalian and insect cells to hydrodynamic forces. Biotechnol Bioeng 80:428–437CrossRefGoogle Scholar
  49. 49.
    Kunas KT, Papoutsakis ET (1990) Damage mechanisms of suspended animal cells in agitated bioreactors with and without bubble entrainment. Biotechnol Bioeng 36:476–483CrossRefGoogle Scholar
  50. 50.
    Chattopadhyay D, Rathman JF, Chalmers JJ (1995) Thermodynamic approach to explain cell adhesion to air-medium interfaces. Biotechnol Bioeng 48:649–658CrossRefGoogle Scholar
  51. 51.
    Ma N, Chalmers JJ, Aunins JG, Zhou W, Xie L (2004) Quantitative studies of cell-bubble interactions and cell damage at different Pluronic F-68 and cell concentrations. Biotechnol Prog 20:1183–1191CrossRefGoogle Scholar
  52. 52.
    Osman JJ, Birch J, Varley J (2001) The response of GS-NS0 myeloma cells to pH shifts and pH perturbations. Biotechnol Bioeng 75:63–73CrossRefGoogle Scholar
  53. 53.
    Sauer PW, Burky JE, Wesson MC, Sternard HD, Qu L (2000) A high-yielding, generic fed-batch cell culture process for production of recombinant antibodies. Biotechnol Bioeng 67:585–597CrossRefGoogle Scholar
  54. 54.
    Lao MS, Toth D (1997) Effects of ammonium and lactate on growth and metabolism of a recombinant Chinese hamster ovary cell culture. Biotechnol Prog 13:688–691CrossRefGoogle Scholar
  55. 55.
    Ozturk SS, Thrift JC, Blackie JD, Naveh D (1997) Real-time monitoring and control of glucose and lactate concentrations in a mammalian cell perfusion reactor. Biotechnol Bioeng 53:372–378CrossRefGoogle Scholar
  56. 56.
    Martinelle K, Westlund A, Haggstrom L (1996) Ammonium ion transport: A cause of cell death. Cytotechnol 22:251–254CrossRefGoogle Scholar
  57. 57.
    Genzel Y, Ritter JB, Konig S, Alt R, Reichl U (2005) Substitution of glutamine by pyruvate to reduce ammonia formation and growth inhibition of mammalian cells. Biotechnol Prog 21:58–69CrossRefGoogle Scholar
  58. 58.
    Yang M, Butler M (2000) Effect of ammonia on the glycosylation of human recombinant erythropoietin in culture. Biotechnol Prog 16:751–759CrossRefGoogle Scholar
  59. 59.
    Gray DR, Chen S, Howarth W, Inlow D, Maiorella BL (1996) CO2 in large-scale and high-density CHO cell perfusion culture. Cytotechnol 22:65–78CrossRefGoogle Scholar
  60. 60.
    deZengotita VM, Schmelzer AE, Miller WM (2002) Characterization of hybridoma cell responses to elevated pCO2 and osmolality: Intracellular pH, cell size, apoptosis, and metabolism. Biotechnol Bioeng 77:369–380CrossRefGoogle Scholar
  61. 61.
    Zhu MM, Goyal A, Rank DL, Gupta SK, Vanden Boom T, Lee SS (2005) Effects of elevated pCO2 and osmolality on growth of CHO cells and production of antibody-fusion protein B1: A case study. Biotechnol Prog 21:70–77CrossRefGoogle Scholar
  62. 62.
    Mostafa SS, Gu X (2003) Strategies for improved dCO2 removal in large-scale fed-batch cultures. Biotechnol Prog 19:45–51CrossRefGoogle Scholar
  63. 63.
    Chen ZL (2004) Temperature shift as a process optimization step for the production of pro-urokinase by a recombinant Chinese hamster ovary cell line in high-density perfusion culture. J Biosci Bioeng 97:239–243Google Scholar
  64. 64.
    Clark KJ, Chaplin FW, Harcum SW (2004) Temperature effects on product-quality-related enzymes in batch CHO cell cultures producing recombinant tPA. Biotechnol Prog 20:1888–1892CrossRefGoogle Scholar
  65. 65.
    Fox SR, Patel UA, Yap MG, Wang DI (2004) Maximizing interferon-gamma production by Chinese hamster ovary cells through temperature shift optimization: Experimental and modeling. Biotechnol Bioeng 85:177–184CrossRefGoogle Scholar
  66. 66.
    Bollati-Fogolin M, Forno G, Nimtz M, Conradt HS, Etcheverrigaray M, Kratje R (2005) Temperature reduction in cultures of hGM-CSF-expressing CHO cells: Effect on productivity and product quality. Biotechnol Prog 21:17–21CrossRefGoogle Scholar
  67. 67.
    Dempsey J, Ruddock S, Osborne M, Ridley A, Sturt S, Field R (2003) Improved fermentation processes for NS0 cell lines expressing human antibodies and glutamine synthetase. Biotechnol Prog 19:175–178CrossRefGoogle Scholar
  68. 68.
    Wong DCF, Wong KTK, Goh LT, Heng CK, Yap MGS (2005) Impact of dynamic online fed-batch strategies on metabolism, productivity and N-glycosylation quality in CHO cell cultures. Biotechnol Bioeng 89:164–177CrossRefGoogle Scholar
  69. 69.
    Dowd JE, Kwok KE, Piret JM (2000) Increased t-PA yields using ultrafiltration of an inhibitory product from CHO fed-batch culture. Biotechnol Prog 16:786–794CrossRefGoogle Scholar
  70. 70.
    Dowd JE, Kwok KE, Piret JM (2001) Predictive modeling and loose-loop control for perfusion bioreactors. Biochem Eng J 9:1–9CrossRefGoogle Scholar
  71. 71.
    Nienow AW, Langheinrich C, Stevenson NC, Emery AN, Clayton TM, Slater NKH (1996) Homogenisation and oxygen transfer rates in large agitated and sparged animal cell bioreactors: Some implications for growth and production. Cytotechnol 22:87–94CrossRefGoogle Scholar
  72. 72.
    Gardner AR, Smith TM (2000) Identification and establishment of operating ranges of critical process variables. In: Sofer G, Zabriskie DW (eds) Biopharmaceutical process validation. Marcel Dekker, New York, pp 61–76Google Scholar
  73. 73.
    Moran EB, McGowan ST, McGuire JM, Frankland JE, Oyebade IA, Waller W, Archer LC, Morris LO, Pandya J, Nathan SR, Smith L, Cadette ML, Michalowski JT (2000) A systematic approach to the validation of process control parameters for monoclonal antibody production in fed-batch culture of a murine myeloma. Biotechnol Bioeng 69:242–255CrossRefGoogle Scholar
  74. 74.
    Lyddiatt A (1981) Downstream processing: Protein recovery. In: Butler M (ed) Mammalian cell biotechnology: a practical approach. IRL Press at Oxford University Press, New York, pp 187–206Google Scholar
  75. 75.
    Bennan J, Bing F, Boone H, Fernandez J, Seely B, van Deinse H, Miller D (2002) Evaluation of extractables from product-contact surfaces. Biopharm Int 15:22–34Google Scholar
  76. 76.
    Kemp G, O’Neil P (2004) Large-scale production of therapeutic antibodies: Considerations for optimizing product capture and purification. In: Subramanian G (ed) Antibodies, vol 1, Production and purification. Kluwer, Boston, pp 75–100CrossRefGoogle Scholar
  77. 77.
    Burton S (2002) A generic approach to the purification of monoclonal antibodies: An alternative to protein A. IBC Conference: antibody production & downstream processing, Feb 13–15, San Diego, CAGoogle Scholar
  78. 78.
    Jacob LR, Frech M (2004) Scale-up of antibody purification. In: Subramanian G (ed) Antibodies, vol 1, Production and purification. Kluwer, Boston, pp 101–131CrossRefGoogle Scholar
  79. 79.
    Gattschalk U (2005) Large scale manufacturing of mAbs and the backlog in bioseparation technologies. IBC Conference: antibody production & downstream processing, March 8–11, San Diego, CAGoogle Scholar
  80. 80.
    Hubbard B (2005) Platform approaches to monoclonal antibody purification. IBC Conference: antibody production & downstream processing, Mar 8–11, San Diego, CAGoogle Scholar
  81. 81.
    Fish B (2002) Taking a monoclonal antibody from mg to kg scale: Production strategies, issues and successes. IBC Conference: Scaling-up From Bench to Clinic and Beyond, Aug 14–16, San Diego, CAGoogle Scholar
  82. 82.
    Aranha-Creado H (1998) Clearance of murine leukaemia virus from monoclonal antibody solutions by a hydrophilic PVDF microporous membrane filter. Biologicals 26:167–172CrossRefGoogle Scholar
  83. 83.
    Rathore A, Velaydhan A (2003) Guidelines for optimization and scale-up in preparative chromatography. Biopharm Int 16:34–42Google Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Marie M. Zhu
    • 1
  • Michael Mollet
    • 1
    • 2
  • Rene S. Hubert
    • 1
  1. 1.Technical Operations, Xencor Inc.MonroviaUSA
  2. 2.Process Development, Medimmune Inc.GaithersburgUSA

Personalised recommendations